相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
Sophia G. Liva et al.
EMBO MOLECULAR MEDICINE (2020)
Phase I study of AR-42 and decitabine in acute myeloid leukemia
Sophia G. Liva et al.
LEUKEMIA & LYMPHOMA (2020)
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
Henrik Jespersen et al.
BMC CANCER (2019)
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
Petros Grivas et al.
CANCER (2019)
Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Blaz Groselj et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU
Ruihao Zhou et al.
ONCOLOGY LETTERS (2018)
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera et al.
FRONTIERS IN ONCOLOGY (2018)
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
Douglas W. Sborov et al.
LEUKEMIA & LYMPHOMA (2017)
Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways
Yi-Jin Chen et al.
PLOS ONE (2017)
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
Laurence Booth et al.
Oncotarget (2017)
Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review
Andreu Porta-Sanchez et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
BAP1, a tumor suppressor gene driving malignant mesothelioma
Mitchell Cheung et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
Sridhar Murahari et al.
BMC CANCER (2017)
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability
Min-Wu Chao et al.
ONCOTARGET (2016)
Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents
Hao Cheng et al.
AAPS JOURNAL (2016)
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production
Weihong Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer
David R. Li et al.
JOURNAL OF UROLOGY (2015)
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
Eudocia Q. Lee et al.
NEURO-ONCOLOGY (2015)
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
Alessandro Canella et al.
ONCOTARGET (2015)
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors
Joseph J. Sacco et al.
ONCOTARGET (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Ahrum Min et al.
BREAST CANCER RESEARCH (2015)
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Michinori Ogura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Mark Kirschbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer
Donatella Del Bufalo et al.
MOLECULAR CANCER (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Edward Seto et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth
Sarah S. Burns et al.
CANCER RESEARCH (2013)
EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
Takayuki Nakagawa et al.
CANCER RESEARCH (2013)
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
Madeleine Duvic et al.
EUROPEAN JOURNAL OF CANCER (2013)
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
Tianzhu Qiu et al.
FUTURE ONCOLOGY (2013)
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
A. Mims et al.
LEUKEMIA (2013)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Solange Landreville et al.
CLINICAL CANCER RESEARCH (2012)
Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas
Abraham Jacob et al.
LARYNGOSCOPE (2012)
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
Bret B. Friday et al.
NEURO-ONCOLOGY (2012)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
John D. Hainsworth et al.
CANCER INVESTIGATION (2011)
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells
Shuhong Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Mario Federico et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Antitumor effects of AR-42, a novel histone deacetylase inhibitor, in embryonal carcinoma
A. S. Bhinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas
Matthew L. Bush et al.
NEURO-ONCOLOGY (2011)
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2011)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
David M. Lucas et al.
PLOS ONE (2010)
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed
Elena Di Gennaro et al.
CANCER BIOLOGY & THERAPY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P. Whitehead et al.
INVESTIGATIONAL NEW DRUGS (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
Scott R. Plotkin et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Neurofibromatosis type 2
Ashok R. Asthagiri et al.
LANCET (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer
Ya-Ting Yang et al.
NEOPLASIA (2009)
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M. Crump et al.
ANNALS OF ONCOLOGY (2008)
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
Nicola L. Steele et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
Johan Vansteenkiste et al.
INVESTIGATIONAL NEW DRUGS (2008)
Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
R. G. Bociek et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
M. Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R. Blumenschein et al.
INVESTIGATIONAL NEW DRUGS (2008)
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
Yen-Shen Lu et al.
HEPATOLOGY (2007)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Ju-Hee Lee et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes
CS Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors
Q Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
Q Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer
T Reid et al.
LUNG CANCER (2004)
分享论文
